CSIMarket
 
Bio rad Laboratories Inc   (NYSE: BIO)
Other Ticker:  
 
 
Price: $239.0700 $-5.91 -2.412%
Day's High: $242.605 Week Perf: 2.92 %
Day's Low: $ 235.78 30 Day Perf: -8.06 %
Volume (M): 50 52 Wk High: $ 387.99
Volume (M$): $ 11,940 52 Wk Avg: $308.72
Open: $243.06 52 Wk Low: $215.38



 Market Capitalization (Millions $) 6,746
 Shares Outstanding (Millions) 28
 Employees 8,030
 Revenues (TTM) (Millions $) 2,566
 Net Income (TTM) (Millions $) -1,844
 Cash Flow (TTM) (Millions $) 85
 Capital Exp. (TTM) (Millions $) 166

Bio Rad Laboratories Inc
Bio-Rad Laboratories Inc. is a prominent multinational corporation specializing in the development and manufacturing of a wide range of products for life science research and clinical diagnostics. The company is based in Hercules, California, and operates in more than 100 countries around the globe, demonstrating its significant international presence and influence within the industry.

History and Background

Founded in 1952 by David and Alice Schwartz, Bio-Rad started as a manufacturer of specialty chemicals intended for the scientific research community. Over the years, the company expanded its focus and expertise, evolving to develop cutting-edge products for various applications in microbiology, genetics, and protein research. This growth was driven by the increasing demand for innovative laboratory solutions, and Bio-Rad quickly earned a reputation as a leader in the field.

Product Portfolio

1. Life Science Division:
- Reagents: Bio-Rad provides a wide array of reagents used in genomic research, including kits for DNA and RNA analysis.
- Instruments: The company manufactures advanced instruments for various life science applications, such as electrophoresis systems, real-time PCR machines, and other analytical devices.
- Software: Bio-Rad develops software solutions that assist researchers in data analysis and management, enhancing workflow efficiency.

2. Clinical Diagnostics Division:
- Bio-Rad's clinical diagnostics division is known for delivering a diverse range of products aimed at diagnosing and managing diseases. This includes:
- Blood typing and transfusion testing products, which are essential for ensuring safe blood transfusions.
- Systems for monitoring infectious diseases, contributing to public health initiatives.
- Diagnostic tools related to diabetes and autoimmunity, which are increasingly important in preventive healthcare.

Commitment to Sustainability

Bio-Rad is dedicated to sustainability and corporate responsibility. The company has implemented various strategies to reduce waste and enhance laboratory efficiency, thereby minimizing its environmental impact. Their commitment extends to designing products that enable researchers to conduct their work more sustainably, fostering a practice of environmental consciousness within the scientific community.

Philanthropy and Community Engagement

In addition to its commitment to sustainability, Bio-Rad is actively involved in philanthropic efforts, focusing on supporting science education and advancing research initiatives. The company engages in multiple programs aimed at driving interest in science and technology among students and providing grants to support educational institutions and scientific research.

Industry Impact and Recognition

As a leading manufacturer in the life sciences and diagnostics sectors, Bio-Rad Laboratories Inc. has positioned itself as a trusted entity for academic and clinical institutions worldwide. The company is recognized for its innovative solutions, consistently pushing the boundaries of what is possible in research and diagnostics.

Overall, Bio-Rad Laboratories Inc. stands out for its extensive product offerings, commitment to quality and innovation, and proactive approach to corporate responsibility and community engagement. It continues to play a vital role in advancing scientific understanding and improving healthcare outcomes globally.


   Company Address: 1000 Alfred Nobel Drive, Hercules, 94547 CA
   Company Phone Number: 724-7000   Stock Exchange / Ticker: NYSE BIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -0.22%    
CTKB   -0.53%    
ILMN   -2.24%    
MTD   -3.55%    
RVTY   -3.2%    
TXG        4.68% 
• View Complete Report
   



Business Update

Bio-Rad Laboratories Outshining Rivals with Remarkable Growth and Profitability,

Published Thu, Nov 21 2024 4:47 PM UTC

Bio-Rad Laboratories: Outperforming Rivals in a Competitive Healthcare Landscape As Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) prepares to engage directly with analysts and investors at Citi s 2024 Global Healthcare Conference, the company stands on firm ground. Under the leadership of CEO Norman Schwartz and CFO Roop K. Lakkaraju, Bio-Rad has managed to navigate a tur...

Bio Rad Laboratories Inc

Bio Rad Laboratories Inc Reports Single Digit Revenue Decline in First Quarter of 20242.

Bio Rad Laboratories Inc, headquartered in Hercules, California, is a global leader in life science research and clinical diagnostics products. The company recently announced its financial results for the fourth quarter and full year ended December 31, 2023.
In terms of net profit per share, Bio Rad Laboratories experienced significant growth. In the most recent fiscal period, the net profit per share soared by 479.74% to $13.45 per share compared to $2.32 per share the year prior. Additionally, the net profit per share surged by 10.7% from $12.15 per share in the previous financial reporting period.

Management Changes

Bio-Rad Laboratories Appoints Roop K. Lakkaraju as CFO to Drive Financial Transformation and Growth

Published Wed, Mar 20 2024 12:30 PM UTC

Bio-Rad Laboratories Appoints Roop K. Lakkaraju as Executive Vice President and Chief Financial Officer
Hercules, California - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a renowned global leader in life science research and clinical diagnostics products, is pleased to announce the appointment of Roop K. Lakkaraju as its new Executive Vice President and Chief Finan...

Bio Rad Laboratories Inc

Bio-Rad Laboratories Inc. Sees Revenue Dip of -6.621% in Q4 2023 Amidst Earnings Decline

Bio-Rad Laboratories Inc, a global leader in life science research and clinical diagnostics products, has recently released its financial results for the fourth quarter of 2023 earnings season. The numbers reveal some interesting facts about the company's performance.
Firstly, the earnings per share (EPS) for the quarter saw a significant decline of -56.74% to $12.15 per share, compared to $28.08 per share in the same period the previous year. However, in a positive turn of events, the EPS increased by 233.79% from $3.64 per share in the prior financial reporting period.

Bio Rad Laboratories Inc

Bio Rad Laboratories Inc. Sees Decline in Revenue Amidst Challenging Third Quarter of 2023



Bio Rad Laboratories Inc, a leading global provider of life science research and clinical diagnostic products, posted impressive financial results for the most recent fiscal period. Despite a decrease in revenue, the company managed to turn around its profitability by presenting a significant increase in Income per Share. This article will analyze Bio Rad Laboratories Inc's financial performance and discuss its future prospects.
Body:
1. Revenue Decline and Profitability Turnaround:
Bio Rad Laboratories Inc experienced a revenue decline of -7.215%, with revenue falling from $680.80 million to $631.68 million compared to the same period a year ago. However, the company managed to reverse its fortunes by reporting a net income of $106.257 million, a substantial improvement compared to a net loss of $-164.232 million in the previous year. This transformation in profitability is reflected in the impressive increase in Income per Share from a loss of $-5.52 to $3.64.







Bio Rad Laboratories Inc's Segments
Life Science    40.21 % of total Revenue
Clinical Diagnostics    59.92 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com